BioNTech SE stock carries a USD 127.44 consensus target after Q2 miss

Published on 09/28/2026 at 13:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioNTech SE stock was last at USD 98.52 on September 25, 2026, with a USD 127.44 consensus target. Q2 revenue fell 59.5 percent year over year.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech SE stock was last at USD 98.52 on Nasdaq on September 25, 2026, down 0.75 percent from the prior session. The valuation debate now pits a weak second quarter against sharply different analyst targets, with Berenberg raising its target to USD 140.00 on September 16.

Quarterly revenue fell 59.5 percent

According to MarketBeat, BioNTech reported Q2 2026 revenue of USD 122.31 million in its August 4 results, down 59.5 percent from the prior-year quarter. Adjusted EPS was a USD 2.53 loss, missing the USD 2.40 consensus loss by USD 0.13.

The figures give investors a concrete counterweight to the pipeline narrative. The same report said revenue missed the USD 180.18 million estimate, leaving the commercial base under pressure while the company continues developing oncology therapies and vaccines.

Analysts disagree on the target

According to Boerse Express on September 22, Berenberg raised its BioNTech target from USD 132.00 to USD 140.00 and reaffirmed a Buy rating based on progress in the clinical pipeline. The report also states that BMO Capital Markets cut its target from USD 128.00 to USD 105.00 and changed its rating from Outperform to Market Perform on September 8.

Jefferies offers a higher reference point: MarketScreener reported on September 16 that the firm kept a Buy rating and a USD 138.00 target. MarketBeat listed a consensus target of USD 127.44 in its August 31 report.

Stock remains below its yearly high

BioNTech's market capitalization was USD 24.7 billion and trading volume was 580,032 shares on September 25, 2026. The 52-week range was USD 79.52 to USD 124.00, putting the last price 20.55 percent below the high.

For investors, the central tension is visible in the numbers: a USD 122.31 million quarterly revenue base and a USD 2.53 adjusted EPS loss contrast with targets between USD 105.00 and USD 140.00. The stock's next move will depend on whether pipeline progress can offset the earnings pressure.